FY2026 EPS Estimates for Cybin Boosted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings estimate for Cybin Inc. to a loss of $2.77 per share, up from a previous forecast of $4.23, and maintains a "Strong-Buy" rating on the stock.
• Cybin's current full-year earnings estimate is projected at $4.76 per share, while Canaccord Genuity set a new price target of $70.00 and also rated the stock as "Buy."
• Institutional investors have shown increased interest in Cybin, with several hedge funds establishing new positions, leading to a total ownership of 17.94% in the company by these investors.

Cybin Inc. (NYSE:CYBN - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2026 earnings per share (EPS) estimates for shares of Cybin in a research note issued to investors on Monday, August 18th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($2.77) per share for the year, up from their prior forecast of ($4.23). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Cybin's current full-year earnings is ($4.76) per share.

Separately, Canaccord Genuity Group cut their price target on Cybin from $73.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. According to MarketBeat.com, Cybin currently has a consensus rating of "Buy" and a consensus price target of $85.00.

Cybin Stock Up 3.3%

CYBN stock traded up $0.23 during mid-day trading on Wednesday, reaching $7.15. 592,928 shares of the company traded hands, compared to its average volume of 320,405. The stock has a market cap of $168.67 million, a price-to-earnings ratio of -1.63 and a beta of 0.68. Cybin has a fifty-two week low of $4.81 and a fifty-two week high of $13.88. The firm's 50 day moving average price is $7.68 and its 200 day moving average price is $7.55.

Hedge Funds Weigh In On Cybin

A number of hedge funds have recently added to or reduced their stakes in CYBN. Tang Capital Management LLC boosted its stake in shares of Cybin by 232.5% in the 4th quarter. Tang Capital Management LLC now owns 1,330,097 shares of the company's stock worth $11,731,000 after buying an additional 930,097 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Cybin in the 4th quarter worth approximately $7,938,000. Acorn Capital Advisors LLC purchased a new position in shares of Cybin in the 4th quarter worth approximately $6,477,000. DCF Advisers LLC purchased a new position in shares of Cybin in the 1st quarter worth approximately $1,281,000. Finally, Bollard Group LLC purchased a new position in shares of Cybin in the 2nd quarter worth approximately $1,317,000. Institutional investors and hedge funds own 17.94% of the company's stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.